Osteoporosis Drug Fosamax Linked to Two Serious Side Effects (BioSpace, 7 January 2009)

UPDATE 1-Ipsen keeps 2009, 2012 goals, to triple trials (Reuters, 8 January 2008)

12 Jan 2009

French drugmaker Ipsen claims it can still reach its 2009 and 2012 targets, which include reaching a 10% share of the US market for its endocrinology drug Somatuline.

Full article

UPDATE 1-Ipsen keeps 2009, 2012 goals, to triple trials (Reuters, 8 January 2008)

Share this story

Top stories

Most read